MIM
IBRX icon

MTM Investment Management’s ImmunityBio IBRX Stock Holding History

MTM Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.76K Hold
1,000
– – ﹤0.01% 546
2026
Q1 		$7.67K Hold
1,000
– – ﹤0.01% 555
2025
Q4 		$1.98K Hold
1,000
– – ﹤0.01% 639
2025
Q3 		$2.46K Hold
1,000
– – ﹤0.01% 635
2025
Q2 		$2.64K Buy
+1,000
New +$2.69K ﹤0.01% 645

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MTM Investment Management's IBRX Position: Q2 2026 in Review

MTM Investment Management held its ImmunityBio (IBRX) position steady in Q2 2026 at 1,000 shares worth $8.76K. The position accounts for ﹤0.01% of the portfolio, ranked #546.

MTM Investment Management first reported a position in IBRX in Q2 2025 and has held it in 5 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • MTM Investment Management held 1,000 shares of ImmunityBio worth $8.76K as of Q2 2026.
  • MTM Investment Management left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of MTM Investment Management's portfolio in Q2 2026, its #546 holding.
  • MTM Investment Management first reported a position in ImmunityBio in Q2 2025 and has held it in 5 quarters since.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on MTM Investment Management's 13F filing for Q2 2026, filed 3 Aug 2026.